GNAS and osteosarcoma: However, the fact that the Gsα mutation did not change through the process of malignant transformation leads us to believe that this mutation has the potential to at least be a clinical marker for distinguishing de novo osteosarcoma (primary osteosarcoma) from secondary osteosarcoma arising from FD.